journal
https://read.qxmd.com/read/36778762/the-cancer-driver-genes-idh1-and-idh2-and-cd204-in-who-grade-4-astrocytoma-crosstalk-between-cancer-metabolism-and-tumour-associated-macrophage-recruitment-in-tumour-microenvironment
#21
JOURNAL ARTICLE
Maher Kurdi, Nasser Mulla, Yousef Katib, Taghreed Alsinani, Sahar Hakamy, Bassam Mj Addas, Husam Malibary, Taher F Halawa, Marwa S Farhan, Eyad Faizo, Saleh Baeesa
PURPOSE: IDH1 and IDH2 are hotspot mutations commonly identified in WHO-grade 4 astrocytomas. Their association with TAMs has never been investigated. We aim to explore the crosstalk between the IDH1/2 mutation metabolic effect and TAMs in tumour microenvironment and how this relationship affects the tumour recurrence. PATIENTS AND METHODS: The study included 20 samples of patients with WHO-grade 4 astrocytoma. The alteration hotspot in codon IDH1R132 and IDH2R172 was examined using direct sequencing...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/36721867/preliminary-assessment-of-safety-and-tolerability-of-avacopan-during-the-early-access-program-for-anca-associated-vasculitis
#22
JOURNAL ARTICLE
Jolijn R van Leeuwen, Tamara Popov, Achim Obergfell, Ton J Rabelink, Y K Onno Teng
No abstract text is available yet for this article.
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/36698375/significance-of-interleukin-23-in-systemic-lupus-patients-relation-to-disease-activity-and-damage-indices
#23
JOURNAL ARTICLE
Maysa M Haroon, Gehan A Hegazy, Mohammed A Hassanien, Olfat Shaker, Wafaa H Hussein
BACKGROUND: Dysregulation of both cellular and humoral immune responses is central in systemic lupus erythematosus (SLE) pathogenetic mechanisms. Proinflammatory cytokines, such as interleukin 23 (IL23), and their roles in promoting such dysregulation have recently been highly considered. This research compared IL23 serum levels in 85 Egyptian SLE patients and 85 healthy controls. Then, IL23 level was correlated to various SLE disease parameters, disease activity, and damage indices. RESULTS: IL23 serum levels were significantly elevated in SLE patients versus healthy individuals...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/36440060/adherence-to-subcutaneous-anti-tumour-necrosis-factor-treatment-in-a-cohort-of-patients-with-rheumatoid-arthritis-before-and-after-the-implementation-of-a-comprehensive-care-model
#24
JOURNAL ARTICLE
Pedro Santos-Moreno, Guillermo Sánchez-Vanegas, Angélica Monterrosa-Blanco, Gabriel-Santiago Rodríguez-Vargas, Manuel Rivero, Pedro Rodriguez, Omar-Javier Calixto, Adriana Rojas-Villarraga, Carlos Alberto Castro
PURPOSE: To assess, in a cohort of patients with rheumatoid arthritis (RA) treated with subcutaneous antitumor necrosis factor drugs (anti-TNFs), the levels of treatment adherence before and after implementing a comprehensive care model (CCM). PATIENTS AND METHODS: An observational study including RA patients under treatment with subcutaneous anti-TNFs (adalimumab, etanercept, and golimumab) selected at convenience was performed; a sample size of 125 patients was calculated...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/36281333/tnf-inhibitors-exert-a-hidden-beneficial-effect-in-the-cardiovascular-lipoprotein-profile-of-ra-patients
#25
JOURNAL ARTICLE
Jaime Calvo Alén, Bernardo Alio Lavin-Gomez, Elena Aurrecoechea, Armando Raul Guerra Ruiz, Víctor Martínez Taboada, Juan Gómez Gerique
Purpose: A high cardiovascular risk has been described in patients with rheumatoid arthritis (RA); the effects of different biological agents have also been described in these patients. The aim of the present study is to examine the effects of tumor necrosis factor inhibitors (TNFi) in the lipoprotein profile of RA patients using a broad laboratory assessment including a large number of non-routine tests. Patients and Methods: RA patients treated with and without TNFi (70 patients in each group) were cross-sectionally compared regarding a broad spectrum of lipoprotein parameters including serum levels of total and HDL, LDL and VLDL cholesterol triglycerides, lipoprotein A (LpA), apolipoprotein A1 (Apo A), B100 (Apo B) and paroxonase...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/36225325/phage-therapy-a-different-approach-to-fight-bacterial-infections
#26
REVIEW
Zigale Hibstu, Habtamu Belew, Yibeltal Akelew, Hylemariam Mihiretie Mengist
Phage therapy is one of the alternatives to treat infections caused by both antibiotic-sensitive and antibiotic-resistant bacteria, with no or low toxicity to patients. It was started a century ago, although rapidly growing bacterial antimicrobial resistance, resulting in high levels of morbidity, mortality, and financial cost, has initiated the revival of phage therapy. It involves the use of live lytic, bioengineered, phage-encoded biological products, in combination with chemical antibiotics to treat bacterial infections...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/36225324/biosimilars-science-implications-and-potential-outlooks-in-the-middle-east-and-africa
#27
REVIEW
Radwa Ahmed Batran, Mai Elmoshneb, Ahmed Salah Hussein, Omar M Hussien, Fady Adel, Reham Elgarhy, Mosaad I Morsi
Biosimilars are biological products that efficiently replicate the function of the originator products. They have changed the prognosis of millions of patients with many serious conditions. The main engine beyond their development is to bring competition into the marketplace, accordingly further the healthcare systems' sustainability. Furthermore, by lowering financial obstacles to biological treatments, biosimilars play a critical role in budgetary redistribution and, hence, promote better allocation of scarce healthcare resources...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/36213816/emerging-therapies-for-huntington-s-disease-focus-on-n-terminal-huntingtin-and-huntingtin-exon-1
#28
REVIEW
M Leontien van der Bent, Melvin M Evers, Astrid Vallès
Huntington's disease is a devastating heritable neurodegenerative disorder that is caused by the presence of a trinucleotide CAG repeat expansion in the Huntingtin gene, leading to a polyglutamine tract in the protein. Various mechanisms lead to the production of N-terminal Huntingtin protein fragments, which are reportedly more toxic than the full-length protein. In this review, we summarize the current knowledge on the production and toxicity of N-terminal Huntingtin protein fragments. Further, we expand on various therapeutic strategies targeting N-terminal Huntingtin on the protein, RNA and DNA level...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/36118798/a-review-on-inflammatory-bowel-diseases-recent-molecular-pathophysiology-advances
#29
REVIEW
Maheeba Abdulla, Nafeesa Mohammed
Inflammatory bowel diseases are considered immune disorders with a complex genetic architecture involving constantly changing endogenous and exogenous factors. The rapid evolution of genomic technologies and the emergence of newly discovered molecular actors are compelling the research community to reevaluate the knowledge and molecular processes. The human intestinal tract contains intestinal human microbiota consisting of commensal, pathogenic, and symbiotic strains leading to immune responses that can contribute and lead to both systemic and intestinal disorders including IBD...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/35957978/biologic-therapy-for-refractory-immune-checkpoint-inhibitor-colitis
#30
REVIEW
Nasser M Alorfi, Mansour Marzouq Alourfi
Immune checkpoint inhibitors (ICI) are treatments for several cancer types. Pathogenesis of ICI-induced colitis is not yet clearly explained as it can be disguised as another form such as inflammatory bowel disease or IBD. Recent studies revealed that ICI-induced colitis is a unique form of colitis wherein the synergy of regulatory T cells with the gut microbiome is involved. Diagnosis of colitis can be done via endoscopic lesions and histopathological methods. A patient with colitis can be compared with someone who has IBD...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/35860386/is-tofacitinib-effectiveness-in-patients-with-rheumatoid-arthritis-better-after-conventional-than-after-biological-therapy-a-cohort-study-in-a-colombian-population
#31
JOURNAL ARTICLE
Pedro Santos-Moreno, Susan Martinez, Linda Ibata, Laura Villarreal, Fernando Rodríguez-Florido, Manuel Rivero, Adriana Rojas-Villarraga, Claudio Galarza-Maldonado
Purpose: Tofacitinib is recommended for treatment of rheumatoid arthritis (RA) in patients with moderate to severe disease activity, but there is not enough evidence on its effectiveness after conventional DMARDs vs its use after biologics. The aim was evaluating the effectiveness of tofacitinib in RA as first-line treatment (after conventional DMARDs) in a real-life setting in Colombian (Latin-American) patients. Patients and Methods: Retrospective cohort study conducted at a specialized center for RA management...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/35836496/promising-stem-cell-therapy-in-the-management-of-hiv-and-aids-a-narrative-review
#32
REVIEW
Usha Rani Kandula, Addisu Dabi Wake
Stem cell therapies are becoming a major topic in biomedical research all over the planet. It may be a viable treatment choice for people suffering from a wide range of illnesses and injuries. It has recently emerged as an extremely intriguing and well-established science and research topic. Expectations have risen due to advancements in therapeutic approaches. Multiple laboratory testing of regulated stem cell culture and derivation is carried out before the formation of stem cells for the use of therapeutic process...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/35769328/successful-treatment-of-an-adult-with-atopic-dermatitis-and-lamellar-ichthyosis-using-dupilumab
#33
Faisal K Binkhonain, Sara Aldokhayel, Hessah BinJadeed, Abdulaziz Madani
Lamellar ichthyosis (LI) is a rare autosomal cornification disorder, with most cases due to a mutation in the transglutaminase-1 (TGM1) gene on chromosome 14. Patients with LI usually present with a collodion membrane and mild erythroderma at birth, with the collodion membranes shedding within the first weeks of life and being replaced by a generalized scale. Typically, LI is managed with oral retinoids, emollients, and keratolytic agents, eg, lactic acid. We report an LI case associated with atopic dermatitis and asthma that showed a marked improvement with dupilumab treatment...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/35747234/biological-therapies-for-the-management-of-enteric-disease-considerations-for-the-clinician
#34
REVIEW
Adam Saleh, Usman Ansari, Shaadi Abughazaleh, Kerri Glassner, Bincy P Abraham
Several biologic therapies have been approved for enteric diseases. We evaluate each biologic's role based on their mechanism of action in treating these conditions. This review examines data on efficacy and safety, as well as considerations for using these therapies in clinical practice in inflammatory bowel diseases, enteric infections-specifically Clostridioides difficile colitis-and potentially in the increasingly prevalent disorder of eosinophilic esophagitis. When choosing an appropriate therapy, it is important to assess patient severity, as most biologics are approved for those with moderate to severe disease activity...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/35721798/biosimilars-in-pediatric-ibd-updated-considerations-for-disease-management
#35
REVIEW
Valeria Dipasquale, Ugo Cucinotta, Claudio Romano
Biologic drugs have significantly modified the pharmacological management of several chronic conditions, including inflammatory bowel diseases (IBD). By contrast, in the last two decades, biologics have been associated with increased direct medical costs. As patents for the reference drugs have expired, the development and commercialization of biosimilars through abbreviated licensing pathways represented an affordable alternative in patients fulfilling the indication for biologics. A growing body of evidence, first in adults and then in the pediatric age group too, has provided reassuring data in terms of efficacy and safety of biosimilars both in naïve patients and in those previously on reference drugs who had to switch to the biosimilar...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/35619987/monoclonal-antibody-therapy-for-the-treatment-of-interstitial-cystitis
#36
REVIEW
Ioannis Mykoniatis, Stavros Tsiakaras, Michael Samarinas, Anastasios Anastasiadis, Evangelos N Symeonidis, Petros Sountoulides
An emerging theory regarding the potentially autoimmune nature of painful bladder syndrome/interstitial cystitis (PBS/IC) had led to several studies being conducted to assess the possible therapeutic effect of immunotherapeutic options for PBS/IC. This review presents the available evidence regarding the potential autoimmunity-based pathogenesis of PBS/IC and focuses on a main representative of the immunotherapeutic modalities for PBS/IC, aiming to summarize, evaluate, and present available data regarding the potential therapeutic role of monoclonal antibodies for PBS/IC patients...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/35592358/targeting-metabolic-reprogramming-of-t-cells-for-enhanced-anti-tumor-response
#37
REVIEW
Yosef Tsegaye Dabi, Henok Andualem, Sisay Teka Degechisa, Solomon Tebeje Gizaw
Cancer immunotherapy is an effective treatment option against cancer. One of the approaches of cancer immunotherapy is the modification of T cell-based anti-tumor immune responses. T-cells, a type of adaptive immune response cells responsible for cell-mediated immunity, have long been recognized as key regulators of immune-mediated anti-tumor immunity. T-cell activities have been reported to be suppressed or enhanced by changes in cell metabolism. Moreover, metabolic reprogramming during activation of T cells is required for the development of distinct differentiation profiles of these cells, which may allow the development of long-term cell-mediated anti-tumor immunity...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/35481241/progress-in-biological-therapies-for-adult-onset-still-s-disease
#38
REVIEW
Paola Galozzi, Sara Bindoli, Andrea Doria, Paolo Sfriso
Adult-onset Still's disease (AOSD) is a rare multifactorial autoinflammatory disorder of unknown etiology, characterized by an excessive release of cytokines triggered by dysregulated inflammation and articular and systemic manifestations. The clinical spectrum of AOSD ranges from self-limiting forms with mild symptoms to life-threatening cases and presents clinical and biological similarities with the juvenile form (sJIA). Nowadays, the advances in biologic agents no longer limit the treatment to NSAIDs, glucocorticoids, or conventional synthetic DMARDs...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/35386275/continuous-use-of-etanercept-during-pregnancy-does-not-affect-tnf-alpha-levels-in-umbilical-cord-blood
#39
Masayuki Nishide, Mayu Yagita, Atsushi Kumanogoh
TNF-alpha-targeted therapies during pregnancy is a topic of interest in rheumatology. Etanercept (ETN) is expected to have lower transplacental transfer, however, clinical evidence is lacking on the usefulness and safeness of continuing etanercept throughout pregnancy. We here described the first reported case of relapsing polychondritis where continuous use of ETN throughout pregnancy was required. The patient was a pregnant Japanese woman who presented with bilateral ear cartilage redness, swelling, saddle nose and severe subglottic oedema...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/35221671/a-non-interventional-multicenter-study-of-first-line-bevacizumab-in-combination-with-chemotherapy-in-patients-with-metastatic-colorectal-cancer-in-lebanon
#40
JOURNAL ARTICLE
Sally Temraz, Fadi Nasr, Joseph Kattan, Dany Abigerges, Walid Moukadem, Fadi Farhat, Layal Maatouk, Georges Chahine, Ali Shamseddine
Purpose: When combined with chemotherapy, bevacizumab improves progression-free survival (PFS) in metastatic colorectal cancer (mCRC). This observational trial was designed to assess the safety and efficacy of bevacizumab plus first-line chemotherapy in a real-world setting in Lebanon. Patients and Methods: A non-interventionaL multicenter study of first-LIne AVastin® (bevacizumab) in combination with chEmotherapy in patients with metastatic colorectal cancer (LLIVE) is a multicenter, prospective, Lebanon-based, observational study that enrolled mCRC patients who received first-line bevacizumab plus chemotherapy combination...
2022: Biologics: Targets & Therapy
journal
journal
41818
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.